Advanced Search

CD19 Stocks List

Symbol Grade Name % Change
SGEN A Seattle Genetics, Inc. 5.09
NKTX A Nkarta, Inc. -1.14
CRBU B Caribou Biosciences, Inc. 8.58
AFMD C Affimed Therapeutics B.V. 0.31
CLLS D Cellectis S.A. -0.95
TCRR F TCR2 Therapeutics Inc. 0.00
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Medicine Cancer Solid Tumors Biopharmaceutical Hematologic Malignancies Lymphoma Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Biotechnology Blastoma Cancer Immunotherapy Carcinoma Cd30 Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Chronic Lymphocytic Leukemia Clinical Medicine Glioblastoma Hodgkin Lymphoma Immunotherapy

Related ETFs - A few ETFs which own one or more of the above listed CD19 stocks.

Symbol Grade Name Weight
XDNA C Kelly CRISPR & Gene Editing Technology ETF 5.23
BBH B Market Vectors Biotech ETF 3.91
BTEC C Principal Healthcare Innovators Index ETF 3.81
GDOC B Goldman Sachs Future Health Care Equity ETF 3.56
FBT B First Trust Amex Biotech Index Fund 3.39
View all CD19 ETFs...
Compare ETFs
Compare BBH to BTEC Compare BBH to GDOC Compare GDOC to FBT

CD19 Stocks Recent News

Date Stock Title
May 16 CLLS Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
May 16 AFMD Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
May 16 SGEN Seagen President, Chairman & CEO Clay Siegall resigns
May 16 SGEN Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
May 14 AFMD What Percentage Of Affimed N.V. (NASDAQ:AFMD) Shares Do Insiders Own?
May 13 CLLS Cellectis S.A.'s (CLLS) CEO Andre Choulika on Q1 2022 Results - Earnings Call Transcript
May 12 NKTX Nkarta GAAP EPS of -$0.79
May 12 CLLS Cellectis Non-GAAP EPS of -$0.64 beats by $0.02, revenue of $3.83M misses by $14.68M
May 12 CLLS Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
May 12 NKTX Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
May 12 CRBU Caribou extends gains as SVB Leerink raises target after early data for CAR-T asset
May 12 CRBU Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
May 12 SGEN Recent 10.0% pullback isn't enough to hurt long-term Seagen (NASDAQ:SGEN) shareholders, they're still up 90% over 5 years
May 12 CRBU Caribou Biosciences rises 27% on early-stage CAR-T therapy data for non-Hodgkin lymphoma
May 12 AFMD Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
May 12 CRBU Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
May 12 TCRR TCR2 Therapeutics GAAP EPS of -$0.76 misses by $0.01
May 12 TCRR TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12 CRBU Here's What Analysts Are Forecasting For Caribou Biosciences, Inc. (NASDAQ:CRBU) After Its First-Quarter Results
May 11 CLLS Cellectis Q1 2022 Earnings Preview
Related Industries: Biotechnology
Related Stock Lists: Medicine Cancer Solid Tumors Biopharmaceutical Hematologic Malignancies Lymphoma Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Biotechnology Blastoma Cancer Immunotherapy Carcinoma Cd30 Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Chronic Lymphocytic Leukemia Clinical Medicine Glioblastoma Hodgkin Lymphoma Immunotherapy

More about CD19
Browse All Tags